Wells Fargo & Company Zentalis Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 20,081 shares of ZNTL stock, worth $74,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,081

Previous 18,446 8.86%

Holding current value

$74,299

Previous $279,000 13.26%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$10.83 - $16.49 $17,707 - $26,961	1,635 Added 8.86%	20,081 $316,000
Q4 2023 Feb 09, 2024	SELL	$9.84 - $20.13 $313,256 - $640,838	-31,835 Reduced 63.31%	18,446 $279,000
Q3 2023 Nov 13, 2023	SELL	$19.63 - $28.29 $294,842 - $424,915	-15,020 Reduced 23.0%	50,281 $1.01 Million
Q2 2023 Aug 15, 2023	BUY	$17.41 - $30.05 $322,851 - $557,247	18,544 Added 39.66%	65,301 $1.84 Million
Q1 2023 May 12, 2023	BUY	$16.14 - $24.94 $704,042 - $1.09 Million	43,621 Added 1390.98%	46,757 $804,000

Q4 2022 Feb 13, 2023	SELL	$18.07 - $25.6 $45,771 - $64,844	-2,533 Reduced 44.68%	3,136 $63,000
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $825,667 - $1.3 Million	-40,814 Reduced 87.8%	5,669 $122,000
Q2 2022 Aug 12, 2022	SELL	$17.91 - $52.25 $1.47 Million - $4.28 Million	-81,935 Reduced 63.8%	46,483 $1.31 Million
Q1 2022 May 16, 2022	SELL	$41.58 - $80.89 $64,947 - $126,350	-1,562 Reduced 1.2%	128,418 $5.92 Million
Q4 2021 Feb 14, 2022	SELL	$66.92 - $84.79 $24.5 Million - $31 Million	-365,751 Reduced 73.78%	129,980 $10.9 Million
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $536,905 - $842,677	-11,465 Reduced 2.26%	495,731 $33 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $18.8 Million - $31.3 Million	503,339 Added 13050.01%	507,196 $27 Million
Q1 2021 May 13, 2021	SELL	$35.69 - $52.72 $464,255 - $685,781	-13,008 Reduced 77.13%	3,857 $167,000
Q4 2020 Feb 09, 2021	BUY	$31.71 - $57.97 $266,839 - $487,817	8,415 Added 99.59%	16,865 $876,000
Q3 2020 Nov 05, 2020	BUY	$27.03 - $47.97 $86,631 - $153,743	3,205 Added 61.11%	8,450 $276,000
Q2 2020 Aug 13, 2020	BUY	$23.2 - $54.8 $121,684 - $287,426	5,245 New	5,245 $252,000

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

76.3M

Call Options Held

68.2K

Put Options Held

2.3K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $211M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Zentalis Pharmaceuticals, Inc. Transaction History